8 hours agoRecognition of remdesivitrifusion recommended
Periskopi(6 years ago)
(6 years ago)The Scientific Committee on Human Medical Products, which operates within the European Bars Agency (EMA), has recommended to this agency conditioned approval of the remdesivivivir bar to treat COVID-19. This is the first bar to be recommended for approval in EMA and the decision, according to the communiqué of this institution, is expected to be taken within days. [...]
The product, according to the communiqué, is recommended for the treatment of adults and for children over 12 infected with COVID-19, who need additional oxygen. These are some of the provisions that the Medical Committee has provided for the use of this shepherd and the categories of patients who should use it.
According to the EMA communiqué, the study generally showed that the patients treated with emdesvir were healed after about 11 days, compared to 15 days of recovery for patients receiving placebo (Plaquebo) is used as an expression for a non-effective medicine given to patients to believe that they are receiving real treatment).
This effect was not noted on patients with mild to medium symptoms, where recovery time was 5 days for both the remdesiviritor and the placebo group. For patients with serious illness, who made up approximately 90 percent of patients who were part of the study, the healing time was 12 days in the remdesiviral group and 18 days in the placebo group”, the EMA communiqué says.
Following the recommendation for approval of this bar, the chairman of the Kosovo Pharmacists' Oda, Arian Jakupi, has said it is important that Kosovo can provide an amount of doses that could be used to patients in serious condition to avoid fatality.
